Patents by Inventor Tim Feuerstein
Tim Feuerstein has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8835441Abstract: The present invention relates generally to amide containing heterobicyclic compounds having the following formulas: wherein R1, R2, D, and Q are as defined in the specification. More particularly, the present invention provides a new class of amide containing heterobicyclic compounds, that exhibit an increased potency in relation to currently known MMP-13 and MMP-3 inhibitors.Type: GrantFiled: June 17, 2011Date of Patent: September 16, 2014Assignee: Amgen Inc.Inventors: Christoph Steeneck, Christian Gege, Frank Richter, Heiko Kroth, Matthias Hochgürtel, Michael Essers, Joshua van Veldhuizen, Bert Nolte, Brian M. Gallagher, Jr., Tim Feuerstein, Matthias Schneider, Torsten Arndt, Hongbo Deng, Ralf Biesinger, Xinyuan Wu, Harald Bluhm, Irving Sucholeiki, Arthur G. Taveras
-
Publication number: 20120015920Abstract: The present invention relates generally to amide group containing pharmaceutical agents, and in particular, to amide containing heterobicyclic metalloprotease inhibitor compounds. More particularly, the present invention provides a new class of heterobicyclic MMP-13 inhibiting and MMP-3 inhibiting compounds, that exhibit an increased potency in relation to currently known MMP-13 and MMP-3 inhibitors.Type: ApplicationFiled: June 17, 2011Publication date: January 19, 2012Applicant: Alantos Pharmaceuticals Holding, Inc.Inventors: Christoph Steeneck, Christian Gege, Frank Richter, Heiko Kroth, Matthias Hochgürtel, Michael Essers, Joshua van Veldhuizen, Bert Nolte, Brian M. Gallagher, JR., Tim Feuerstein, Matthias Schneider, Torsten Arndt, Hongbo Deng, Ralf Biesinger, Xinyuan Wu, Harald Bluhm, Irving Sucholeiki, Arthur G. Taveras
-
Patent number: 8076330Abstract: The present invention relates generally to pyrrolidine and thiazolidine DPP-IV inhibitor compounds. The present invention also provides synthetic methods for preparation of such compounds, methods of inhibiting DPP-IV using such compounds and pharmaceutical formulations containing them for treatment of DPP-IV mediated diseases, in particular, Type-2 diabetes.Type: GrantFiled: January 13, 2011Date of Patent: December 13, 2011Assignee: Amgen Inc.Inventors: Heiko Kroth, Tim Feuerstein, Frank Richter, Jürgen Boer, Michael Essers, Bert Nolte, Matthias Schneider, Matthias Hochgürtel, Fritz-Frieder Frickel, Arthur G. Taveras, Christoph Steeneck
-
Publication number: 20110112051Abstract: The present invention relates generally to pyrrolidine and thiazolidine DPP-IV inhibitor compounds. The present invention also provides synthetic methods for preparation of such compounds, methods of inhibiting DPP-IV using such compounds and pharmaceutical formulations containing them for treatment of DPP-IV mediated diseases, in particular, Type-2 diabetes.Type: ApplicationFiled: January 13, 2011Publication date: May 12, 2011Applicant: Alantos Pharmaceuticals Holding, Inc.Inventors: Heiko KROTH, Tim Feuerstein, Frank Richter, Jürgen Boer, Michael Essers, Bert Nolte, Matthias Schneider, Matthias Hochguertel, Fritz-Frieder Frickel, Arthur Taveras, Christoph Steeneck
-
Patent number: 7795245Abstract: The present invention relates generally to amide group containing pharmaceutical agents, and in particular, to amide containing heterobicyclic metalloprotease inhibitor compounds having the following formulas: wherein R1, R2, R3, and R4 are as defined in the specification. More particularly, the present invention provides a new class of heterobicyclic MMP-13 inhibiting and MMP-3 inhibiting compounds amide containing heterobicyclic compounds, that exhibit an increased potency in relation to currently known MMP-13 and MMP-3 inhibitors.Type: GrantFiled: December 7, 2007Date of Patent: September 14, 2010Assignee: Atlantos Pharmaceuticals Holding, Inc.Inventors: Christoph Steeneck, Christian Gege, Frank Richter, Heiko Kroth, Matthias Hochgurtel, Michael Essors, Joshua Van Veldhuizen, Bert Nolte, Brian M. Gallagher, Jr., Tim Feuerstein, Matthias Schneider, Torsten Arndt, Hongbo Deng, Ralf Biesinger, Xinyuan Wu, Harald Bluhm, Irving Sucholeiki, Arthur G. Taveras
-
Publication number: 20100009961Abstract: The present invention relates generally to pyrrolidine and thiazolidine DPP-IV inhibitor compounds. The present invention also provides synthetic methods for preparation of such compounds, methods of inhibiting DPP-IV using such compounds and pharmaceutical formulations containing them for treatment of DPP-IV mediated diseases, in particular, Type-2 diabetes.Type: ApplicationFiled: June 26, 2009Publication date: January 14, 2010Applicant: Alantos Pharmaceuticals Holding, Inc.Inventors: Heiko Kroth, Tim Feuerstein, Frank Richter, Jurgen Boer, Michael Essers, Bert Nolte, Matthias Schneider, Matthias Hochguertel, Fritz-Frieder Frickel, Arthur Taveras, Christoph Steeneck
-
Publication number: 20090312312Abstract: The present invention relates generally to amide group containing pharmaceutical agents, and in particular, to amide containing heterobicyclic metalloprotease inhibitor compounds. More particularly, the present invention provides a new class of heterobicyclic MMP-13 inhibiting and MMP-3 inhibiting compounds, that exhibit an increased potency in relation to currently known MMP-13 and MMP-3 inhibitors.Type: ApplicationFiled: February 12, 2009Publication date: December 17, 2009Applicant: ALANTOS PHARMACEUTICALS HOLDING, INC.Inventors: Christoph STEENECK, Christian GEGE, Frank RICHTER, Heiko KROTH, Matthias HOCHGURTEL, Michael ESSERS, Joshua VAN VELDHUIZEN, Bert NOLTE, Brian M. GALLAGHER, JR., Tim FEUERSTEIN, Matthias SCHNEIDER, Torsten ARNDT, Hongbo DENG, Ralf BIESINGER, Xinyuan WU, Harald BLUHM, Irving SUCHOLEIKI, Arthur G. TAVERAS
-
Patent number: 7553861Abstract: The present invention relates generally to pyrrolidine and thiazolidine DPP-IV inhibitor compounds. The present invention also provides synthetic methods for preparation of such compounds, methods of inhibiting DPP-IV using such compounds and pharmaceutical formulations containing them for treatment of DPP-IV mediated diseases, in particular, Type-2 diabetes.Type: GrantFiled: April 21, 2006Date of Patent: June 30, 2009Assignee: Alantos Pharmaceuticals Holding, Inc.Inventors: Heiko Kroth, Tim Feuerstein, Arthur Taveras
-
Publication number: 20090137547Abstract: The present invention relates generally to amide group containing pharmaceutical agents, and in particular, to amide containing heterobicyclic metalloprotease inhibitor compounds. More particularly, the present invention provides a new class of heterobicyclic MMP-13 inhibiting and MMP-3 inhibiting compounds, that exhibit an increased potency in relation to currently known MMP-13 and MMP-3 inhibitors.Type: ApplicationFiled: December 7, 2007Publication date: May 28, 2009Inventors: Christoph Steeneck, Christian Gege, Frank Riohter, Holko Kroth, Mouhlee Hochgueriel, Michael Essors, Joshua Van Veldhulzen, Bert Nolte, Brian M. Gallaghor, JR., Tim Feuerstein, Matthias Schneider, Toralen Arndt, Hongbo Deng, Ralf Blesinger, Xinyuan Wu, Harald Bluhm, Irving Sucholelld, Arthur G. Taverse
-
Publication number: 20080176870Abstract: The present invention relates generally to heterobicyclic containing pharmaceutical agents, and in particular, to heterobicyclic metalloprotease inhibitor compounds. More particularly, the present invention provides a new class of heterobicyclic metalloprotease inhibiting compounds that exhibit an increased potency in relation to currently known metalloprotease inhibitors.Type: ApplicationFiled: November 20, 2007Publication date: July 24, 2008Inventors: Bert Nolte, Irving Sucholeiki, Tim Feuerstein, Brian M. Gallagher, Xinyuan Wu, Christoph Steeneck, Christian Gege, Hongbo Deng, Joshua Van Veldhuizen, Arthur Taveras
-
Publication number: 20080161300Abstract: The present invention relates generally to amide group containing pharmaceutical agents, and in particular, to amide containing heterobicyclic metalloprotease inhibitor compounds. More particularly, the present invention provides a new class of heterobicyclic MMP-13 inhibiting and MMP-3 inhibiting compounds, that exhibit an increased potency in relation to currently known MMP-13 and MMP-3 inhibitors.Type: ApplicationFiled: December 7, 2007Publication date: July 3, 2008Applicant: Alantos Pharmaceuticals Holding, Inc.Inventors: Christoph Steeneck, Christian Gege, Frank Richter, Heiko Kroth, Matthias Hochgurtel, Michael Essers, Joshua Van Veldhuizen, Bert Nolte, Brian Gallagher, Tim Feuerstein, Matthias Schneider, Torsten Arndt, Hongbo Deng, Ralf Beisinger, Xinyuan Wu, Harald Bluhm, Irving Sucholeiki, Arthur Taveras
-
Publication number: 20070155738Abstract: The present invention relates generally to amide group containing pharmaceutical agents, and in particular, to amide containing heterobicyclic metalloprotease inhibitor compounds. More particularly, the present invention provides a new class of heterobicyclic MMP-13 inhibiting and MMP-3 inhibiting compounds, that exhibit an increased potency in relation to currently known MMP-13 and MMP-3 inhibitors.Type: ApplicationFiled: November 20, 2006Publication date: July 5, 2007Inventors: Christoph Steeneck, Christian Gege, Frank Richter, Heiko Kroth, Matthias Hochguertel, Michael Essers, Joshua Van Veldhuizen, Bert Nolte, Brian Gallagher, Tim Feuerstein, Matthias Schneider, Torsten Arndt, Hongbo Deng, Ralf Biesinger, Xinyuan Wu, Harald Bluhm, Irving Sucholeiki, Arthur Taveras
-
Publication number: 20060293345Abstract: The present invention relates generally to amide group containing pharmaceutical agents, and in particular, to amide containing heterobicyclic metalloprotease inhibitor compounds. More particularly, the present invention provides a new class of heterobicyclic MMP-13 inhibiting compounds, that exhibit an increased potency in relation to currently known MMP-13 inhibitors.Type: ApplicationFiled: May 22, 2006Publication date: December 28, 2006Inventors: Christoph Steeneck, Christian Gege, Frank Richter, Matthias Hochguertel, Tim Feuerstein, Harald Bluhm, Irving Sucholeiki, Jurgen Boer, Xinyuan Wu, Matthias Schneider, Bert Nolte, Brian Gallagher, Joshua Van Veldhuizen, Hongbo Dong, Michael Essers, Heiko Kroth, Andrew Kiely, Timothy Powers, Arthur Taveras
-
Publication number: 20060270701Abstract: The present invention relates generally to pyrrolidine and thiazolidine DPP-IV inhibitor compounds. The present invention also provides synthetic methods for preparation of such compounds, methods of inhibiting DPP-IV using such compounds and pharmaceutical formulations containing them for treatment of DPP-IV mediated diseases, in particular, Type-2 diabetes.Type: ApplicationFiled: April 21, 2006Publication date: November 30, 2006Inventors: Heiko Kroth, Tim Feuerstein, Frank Richter, Jurgen Boer, Michael Essers, Bert Nolte, Matthias Schneider, Matthias Hochguertel, Fritz-Frieder Frickel, Arthur Taveras